ReviewEye (London, England)2020
Retinopathy of prematurity treatment: Asian perspectives.
Review in Eye (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 57 citations in OpenAlex.
- Safety and efficacy of ripasudil eye drops in preterm infants with retinopathy of prematurity: phase 1/2, open label, single-arm trial.Japanese journal of ophthalmology · 2024Trial
- Validation of the DIGIROP 2.0 Models in predicting the risk of treatment-requiring retinopathy of prematurity in a Taiwanese cohort.Eye (London, England) · 2026Article
- Evaluation of regression, reactivation, retreatment and retinal detachment after injections of three different anti-VEGF drugs for retinopathy of prematurity.Scientific reports · 2026Article
- Retinopathy of Prematurity (ROP): Are We There Yet?Medicina (Kaunas, Lithuania) · 2026Review
- Analysis of risk factors for retinopathy of prematurity: a single-center retrospective cohort study.Translational pediatrics · 2025Article
- The aftermath of retinopathy of prematurity blindness.Eye (London, England) · 2025Article
- Abnormal Expression of Peripheral Blood Leukocyte Surface Markers in Retinopathy of Prematurity Patients.Journal of multidisciplinary healthcare · 2025Article
- OCTA-based evaluation of the correlation between macular retinal and choroidal structural characteristics and refractive status in patients with retinopathy of prematurity.Frontiers in pediatrics · 2025Article
- Multi-omics integration identifies key biomarkers in retinopathy of prematurity through 16S rRNA sequencing and metabolomics.Frontiers in microbiology · 2025Article
- Retinopathy of Prematurity (ROP): An Overview of Biomarkers in Various Samples for Prediction, Diagnosis, and Prognosis.Clinical ophthalmology (Auckland, N.Z.) · 2025Review
- Computer-aided detection of retinopathy of prematurity severity assessment via vessel tortuosity measurement in preterm infants' fundus images.Eye (London, England) · 2024Article
- Long-term follow-up of the cognitive function in children after intravitreal ranibizumab for retinopathy of prematurity.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024Article
- Analysis of research hotspots and trends in pediatric ophthalmopathy based on 10 years of WoSCC literature.Frontiers in pediatrics · 2024Article
- Human umbilical cord mesenchymal stem cells derived-exosomes on VEGF-A in hypoxic-induced mice retinal astrocytes and mice model of retinopathy of prematurity.International journal of ophthalmology · 2024Article
- Retinopathy of prematurity in India - what can we learn from the polio legacy?The Lancet regional health. Southeast Asia · 2023Review
- Refractive status and retinal morphology in children with a history of intravitreal ranibizumab for retinopathy of prematurity.European journal of pediatrics · 2023Article
- Latest Trends in Retinopathy of Prematurity: Research on Risk Factors, Diagnostic Methods and Therapies.International journal of general medicine · 2023Review
- Research Progress and Potential Applications of Spermidine in Ocular Diseases.Pharmaceutics · 2022Review
- Novel Potential Biomarkers for Retinopathy of Prematurity.Frontiers in medicine · 2022Review
- Tailoring Screening Guidelines for Retinopathy of Prematurity in Egypt: An Exploratory Multicentric Study.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinopathy of prematurity (ROP) is a vasoproliferative disease of developing retinal vessels that affects premature infants and can lead to severe and irreversible visual loss if left untreated. India and some other Asian countries are in the middle of a 'third ROP epidemic'. Blindness due to ROP is largely preventable if appropriate, adequate and accessible screening programmes are available. Screening of the premature babies is the first step in ROP management. With the increase in use of tele-screening techniques, more premature babies have been brought under the screening network both from urban and rural regions. Laser photocoagulation to the avascular retina using indirect ophthalmoscopy delivery system is the gold standard for ROP treatment and is usually done under topical anaesthesia in the Asian region in contrast to the western world. Use of intravitreal anti-vascular endothelial growth factors (VEGF) although controversial in management of ROP has been found to be effective in various Asian studies as well. ROP surgery in India and other middle-income Asian countries is largely performed only in few tertiary eye care centres. Poor visual prognosis, late presentation with advanced retinal detachments, lack of adequate number of trained paediatric retinal surgeons and paediatric anaesthetists also contribute to this problem. This current paper summarizes the Asian experience of ROP management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.